user
menu
letter
Sign InRegister
langEnglisharrow

LY75

LY75

LY75 Overview

Molecule Name
Lymphocyte antigen 75
Synonyms
LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
LY75，CD205，Lymphocyte Antigen 75，C-Type Lectin Domain Family 13 Member B，CLEC13B，DEC-205，CD205 Antigen，Gp200-MR6，Ly-75
Background
lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.

LY75 Product List

Species
  • Human（1）
  • Mouse（1）
Tag
  • His Tag（2）
Host
  • HEK293（2）
Conjugate
  • Unconjugated（2）
Grade
  • RUO（2）
Low Endotoxin
  • No（2）
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
LY75
LY5-H52H3
Human LY75 / CD205 Protein, His Tag
Human
HEK293
SDS-PAGE

$360.00

100ug
LY75
LY5-M52H5
Mouse LY75 / CD205 Protein, His Tag (MALS verified)
Mouse
HEK293
MALSSDS-PAGE

$360.00

100ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Product InquiryRequest Customization
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Oberotatug ravtansineOBT-076; MEN1309/OBT076; MEN-1309Phase 1 ClinicalMenarini, Oxford Biotherapeutics Ltd
Carcinoma, Adenoid Cystic; Head and Neck Neoplasms; Lymphoma, Non-Hodgkin; Solid tumours
Details
Customer Reviews